Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.41
UNSPSC Code:
12352203
Species reactivity:
(Burkholderia (Pseudomonas)pyrrocinia)
Species reactivity:
-
Application:
—
Citations:
10
form
liquid
species reactivity
(Burkholderia (Pseudomonas)pyrrocinia)
concentration
~1 mg/mL
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
General description
Burkholderia pyrrocinia (previously also known as Burkholderia Pseudomonas) ) belongs to the Burkholderia cepacia complex (Bcc). Burkholderia cepacia complex is a group of at least 20 gram negative bacterial species that are widely distributed in the natural environment such as, soil and water.1 These bacteria have unusually large genomes (7.5-8.5 Mb).2 B. cepacia are opportunistic and nosocomial pathogens that affect mostly immunocompromised individuals such as cystic fibrosis (CF) patients and cause respiratory illness and chronic inflammation.3First, the bacterium initiates primary infection in the respiratory mucosa followed by spreading to adjacent organs and establishing the “cepacia syndrome.
Application
The antibody may be used in various immunochemical techniques including Immunoblotting. Detection of the Burkholderia pyrrocinia bands by Immunoblotting is specifically inhibited by the immunogen.
Biochem/physiol Actions
B. cepacia has the ability to survive intracellularly in alveolar phagocytes and respiratory epithelial cells.8 Moreover, B. cepacia produces quorum sensing (QS) molecules that control virulence factor expression and biofilm formation that shields the bacteria from immune response and antibiotic treatment.1 Bcc are resistant to various types of antibiotics such as, quinolones, aminoglycosides and β-lactams.1
Anti-Burkholderia pyrrocinia antibody recognizes B. pyrrocinia lysate and whole dead bacteria.
Physical form
Supplied as a solution in 0.01 M phosphate buffered saline pH 7.4, containing 15 mM sodium azide as a preservative.
Preparation Note
For continuous use, store at 2-8°C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
Disclaimer
Unless otherwise stated in our catalog our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
低风险生物材料
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Naomi Hauser et al.
Case reports in infectious diseases, 2015, 537627-537627 (2015-09-12)
Burkholderia (formerly Pseudomonas) cepacia complex is a known serious threat to patients with cystic fibrosis, in whom it has the potential to cause the fatal combination of necrotizing pneumonia, worsening respiratory failure, and bacteremia, known as Cepacia syndrome. The potential
Umadevi S Sajjan et al.
Cellular microbiology, 8(9), 1456-1466 (2006-08-23)
We investigated the trafficking of Burkholderia cenocepacia, an opportunistic respiratory pathogen of persons with cystic fibrosis (CF), in immortalized CF airway epithelial cells in vitro. Our results indicate that bacteria enter cells in a process involving actin rearrangement. Whereas both
Peter Vandamme et al.
Systematic and applied microbiology, 34(2), 87-95 (2011-01-25)
The Burkholderia cepacia complex is a group of closely related species with conflicting biological properties. Triggered by the devastating effect of pulmonary infections in cystic fibrosis patients, the scientific community generated an unusually large amount of taxonomic data for these
A Isles et al.
The Journal of pediatrics, 104(2), 206-210 (1984-02-01)
The prevalence of Pseudomonas cepacia infection increased from 10% in 1971 to 18% by 1981 in a population of approximately 500 patients with cystic fibrosis. Carriage of P. aeruginosa has remained unchanged at 70% to 80% over the same period.
Pitchaipillai Sankar Ganesh et al.
Microbiology and immunology, 64(2), 87-98 (2019-11-27)
Burkholderia cepacia complex (Bcc) are opportunistic pathogens implicated with nosocomial infections, and high rates of morbidity and mortality, especially in individuals with cystic fibrosis (CF). B. cepacia are naturally resistant to different classes of antibiotics, and can subvert the host
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service